Evidence map›Paper›PMID 31545130›Full record

ArticleHuman vaccines & immunotherapeutics2020

Priming effect of bivalent and quadrivalent vaccine for HPV 31/33/45/52: an exploratory analysis from two clinical trials.

Chantal Sauvageau, Gitika Panicker, Elizabeth R Unger, Gaston De Serres, John Schiller, Manale Ouakki, Vladimir Gilca

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Human vaccines & immunotherapeutics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Chantal SauvageauDivision of Biological Risks, Quebec Public Health Institute, Quebec, Quebec, Canada.
Gitika PanickerDivision of High-Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Georgia, Atlanta, USA.
Elizabeth R UngerDivision of High-Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Georgia, Atlanta, USA.
Gaston De SerresDivision of Biological Risks, Quebec Public Health Institute, Quebec, Quebec, Canada.
John SchillerLaboratory of Cellular Oncology, National Cancer Institute, Bethesda, MD, USA.
Manale OuakkiDivision of Biological Risks, Quebec Public Health Institute, Quebec, Quebec, Canada.
Vladimir GilcaDivision of Biological Risks, Quebec Public Health Institute, Quebec, Quebec, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The main objective of this

Indexed as

Papillomavirus InfectionsPapillomavirus VaccinesAntibodies, ViralHuman papillomavirus 31HumansVaccines, CombinedAntibodies, ViralPapillomavirus VaccinesVaccines, CombinedClinical trialHuman papillomavirusImmunogenicityVaccination

Identifiers

PMID31545130
PMCPMC7227663

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.